1.A clinical study on histiocytosis X.
Sang Oh NA ; Joong Gon KIM ; Hyo Seop AHN
Journal of the Korean Pediatric Society 1989;32(11):1510-1519
No abstract available.
Histiocytosis*
;
Histiocytosis, Langerhans-Cell*
2.A Case of Letterer-Siwe Disease.
Suh Hong HA ; Jeong Sil HAN ; Sung Won KIM ; Kyung Tae KIM ; Kil Hyun KIM ; Chung Hee CHI
Journal of the Korean Pediatric Society 1987;30(3):335-341
No abstract available.
Histiocytosis, Langerhans-Cell*
4.Infantile Scabies Masquerading as Langerhans Cell Histiocytosis.
Yoon Seok YANG ; Yun Sun BYUN ; Jin Hye KIM ; Hye One KIM ; Chun Wook PARK
Annals of Dermatology 2015;27(3):349-351
No abstract available.
Histiocytosis, Langerhans-Cell*
;
Scabies*
5.A Case of Report of Letterer-Siwe Disease.
Nam Heon KIM ; Jung Ho LEE ; In Ho KIM ; Churl Young CHUNG ; Jong Eun JOO ; Ill Hyang KO
Journal of the Korean Pediatric Society 1981;24(12):1213-1217
No abstract available.
Histiocytosis, Langerhans-Cell*
6.The research progress on Langerhans cell tumor - review.
Jia ZHANG ; Yi-Ni WANG ; Zhao WANG
Journal of Experimental Hematology 2012;20(4):1042-1046
Langerhans cell tumor is a kind of tumor that originates from Langerhans cells (LC) and maintain their specific phenotype profile and ultrastructural features. Based on cell morphology, immunohistochemical and ultrastructural characteristics, Langerhans cell tumor has two main subcategories: Langerhans cell histiocytosis (LCH) and Langerhans cell sarcoma (LCS). LCH is a benign clonal proliferative disease of the LC, whereas LCS is an extremely rare neoplastic proliferation of Langerhans cells with overtly malignant cytologic features and spreads aggressively, which is considered to be a high level malignant type of LCH. Both LCH and LCS can involved various tissues and organs and have complex and diverse clinical manifestation, which cause different severity. The diagnosis depends on histopathological morphology and immunohistochemistry; the electron microscopy was used to assists diagnosis when necessary. The treatment includes surgery, chemotherapy, radiotherapy, immunotherapy and hematopoietic stem cell transplantation, etc, but lack of generally accepted optimal treatment options currently, individualized treatment is needed. The prognosis of LCH is primarily related to the number of damaged organ, while LCS has a poor overall prognosis as its invasion and rapid progress. This article reviews the pathogenesis, clinical manifestations, diagnosis, treatment and prognosis of both LCH and LCS.
Histiocytosis, Langerhans-Cell
;
Humans
7.Histiocytosis-X with Chronic Weeping Ulcers in the Anogenital Areas.
Young Ho SANG ; In Chul CHOI ; Jae Bok JUN ; Do Won KIM ; Sang Lip CHUNG
Annals of Dermatology 1990;2(2):128-131
No abstract available.
Histiocytosis, Langerhans-Cell*
;
Ulcer*
8.Gastric Langerhans Cell Histiocytosis: Case Report and Review of the Literature.
So Jung LEE ; Chung Su HWANG ; Gi Young HUH ; Chang Hun LEE ; Do Youn PARK
Journal of Pathology and Translational Medicine 2015;49(5):421-423
No abstract available.
Histiocytosis, Langerhans-Cell*
9.Bronchial Washing Cytology of Pulmonary Langerhans Cell Histiocytosis: A Case Report.
Taeyeong KIM ; Hyeong Ju KWON ; Minseob EOM ; Sang Wook KIM ; Min Hi SIN ; Soon Hee JUNG
Journal of Pathology and Translational Medicine 2017;51(4):444-447
No abstract available.
Histiocytosis, Langerhans-Cell*
10.Recent Updates in Langerhans Cell Histiocytosis
Kyung Nam KOH ; Ho Joon IM ; Jong Jin SEO
Clinical Pediatric Hematology-Oncology 2015;22(1):15-21
Langerhans cell histiocytosis (LCH) encompasses a wide range of clinical presentation and its clinical course varies widely from spontaneous regression to severe disseminated disease with the risk of permanent consequences. Although pathogenesis of LCH has been a conundrum, recent advances have led to a better understanding of the molecular pathogenesis of the disease. Especially, advanced genomic analyses have suggested that LCH is a disorder of MAPK pathway mutations. Optimal treatment for LCH has not been established yet. Histiocyte Society has launched a new international multi-center clinical trial, LCH-IV to solve remaining major issues in the treatment of LCH. The aim of this review is to provide an overview of recent understandings on the pathogenesis and treatment of LCH.
Histiocytes
;
Histiocytosis, Langerhans-Cell
Result Analysis
Print
Save
E-mail